Draft scope and provisional stakeholder list comments table (post-referral) (PDF 129 KB) Published: 02 July 2025
Suspended: The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that markets histamine
As you will be aware The Department for Health & Social Care has asked NICE to conduct an appraisal of Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] Please note that following on from a request received from the company this appraisal have been scheduled into the work programme and the ap
NICE must unfortunately postpone the first committee discussion for this topic, scheduled for 4 February 2026. We will instead reschedule the first committee discussion to 9 April 2026.